Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -64.2%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $3M | $3M | $1M | $151M | $537M | $794M | $1.5B | $1.5B | $1.4B | $479M |
| Enterprise Value | $-856908 | $-747196 | $-1682678 | $-1559865 | $149M | $534M | $787M | $1.4B | $1.5B | $1.4B | $476M |
| P/E Ratio → | -0.24 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | 729.06 | 1263.07 | 1025.39 |
| P/B Ratio | 0.16 | 0.21 | 0.18 | 0.09 | 11.23 | 17.61 | 17.98 | 20.95 | 16.90 | 86.76 | 43.24 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | 717.21 | 1251.07 | 1018.76 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% |
| Operating Margin | — | — | — | — | — | — | — | — | -525.8% | -1139.5% | -3615.0% |
| Net Profit Margin | — | — | — | — | — | — | — | — | -483.6% | -1133.5% | -3630.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -64.2% | -64.2% | -49.8% | -50.6% | -81.4% | -87.0% | -50.5% | -25.9% | -19.0% | -91.5% | -103.9% |
| ROA | -55.5% | -55.5% | -42.8% | -41.7% | -67.2% | -73.0% | -44.4% | -24.4% | -17.9% | -68.2% | -83.3% |
| ROIC | -54.4% | -54.4% | -41.4% | -49.5% | -67.1% | -75.6% | -49.4% | -28.4% | -24.2% | -172.5% | -99.8% |
| ROCE | -53.0% | -53.0% | -41.6% | -54.8% | -79.9% | -87.6% | -52.7% | -28.3% | -20.7% | -89.4% | -100.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.00 | 0.02 | 0.01 | 0.00 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.25 | -0.28 | -0.20 | -0.13 | -0.09 | -0.15 | -0.22 | -0.27 | -0.82 | -0.28 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -418.53 | -681.09 | -82.10 | -764.67 | -974.52 | -678.06 | -255.12 | -252.33 | -251.97 |
Net cash position: cash ($4M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.55 | 6.55 | 7.42 | 4.81 | 4.76 | 6.13 | 6.47 | 11.02 | 33.41 | 4.98 | 3.44 |
| Quick Ratio | 6.55 | 6.55 | 7.42 | 4.81 | 4.76 | 6.13 | 6.47 | 11.02 | 33.41 | 5.00 | 3.49 |
| Cash Ratio | 6.38 | 6.38 | 7.06 | 4.60 | 4.46 | 5.92 | 6.35 | 10.89 | 33.33 | 4.94 | 3.37 |
| Asset Turnover | — | — | — | — | — | — | — | — | 0.02 | 0.06 | 0.03 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | 9.13 | 52.14 | 221.97 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $4M | $930822 | $230794 | $2M | $2M | $1M | $1M | $1M | $832489 | $758310 |
Imminent insolvency and dilution
Based on reported figures, GLMD trades at a price-to-book ratio of 0.16, which, according to recent SEC filings, suggests the market is pricing the firm for liquidation rather than as a going concern with a viable path to commercializing its lead asset, Aramchol.
The extremely low P/B multiple indicates that investors assign negligible value to the company's intellectual property and clinical pipeline. This valuation gap relative to peers like Madrigal Pharmaceuticals suggests that the market has largely discounted the probability of successful Phase III outcomes, viewing the current equity as a high-risk option on binary clinical events.
As reported in financial statements, GLMD's ROIC has remained consistently negative, reaching -16.5% in 2025Q4, which highlights the company's inability to generate productive returns on the capital deployed into its long-duration clinical development programs over the past several years.
The negative ROIC trend reflects the structural reality of a pre-revenue biotech where capital is consumed by R&D rather than invested in income-generating assets. This persistent decay in returns suggests that management's focus on the SCD1 pathway has yet to yield the clinical milestones necessary to justify the ongoing dilution of shareholder capital.
According to recent quarterly filings, the company's current ratio has fluctuated significantly, yet the absolute cash position of $3.98M as of 2025Q4 indicates a precarious liquidity profile that leaves little room for operational error or unforeseen delays in the ARMOR study.
While the current ratio appears superficially high due to the lack of short-term liabilities, the absolute dollar amount of cash is insufficient to sustain the company's burn rate through a full clinical cycle. Investors should monitor the company's ability to secure non-dilutive financing or partnerships, as the current liquidity position appears inadequate for long-term survival.
Based on an analysis of the company's financial structure, the current ratio is the most commonly misapplied metric for GLMD, as it obscures the reality that the firm's assets are largely illiquid clinical trial costs rather than readily convertible working capital.
Using the current ratio to assess solvency in a pre-revenue biotech is misleading because it ignores the binary nature of clinical trial success. A more appropriate focus would be the 'cash runway' relative to monthly burn, as the company's ability to continue operations depends entirely on external capital markets rather than the efficiency of its current asset base.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GLMD stock.
Galmed Pharmaceuticals Ltd.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Galmed Pharmaceuticals Ltd.'s return on equity (ROE) is -64.2%. The historical average is -60.5%.
Based on historical data, Galmed Pharmaceuticals Ltd. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.